Abrocitinib
Abrocitinib may be ‘promising treatment’ for prurigo nodularis, chronic pruritus
Abrocitinib may be an effective and well-tolerated treatment for adults with prurigo nodularis and chronic pruritus of unknown origins, according to a study.
VIDEO: ‘No new safety events’ for abrocitinib in atopic dermatitis
In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the Janus kinase 1 inhibitor abrocitinib from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.
Abrocitinib downregulates genes linked to inflammation in patients with atopic dermatitis
Abrocitinib downregulated genes associated with inflammation, epidermal hyperplasia, and T helper 2 and T helper 22 responses in the skin of patients with moderate to severe atopic dermatitis, according to a study published in Allergy.
Q&A: Carmella Evans-Molina, MD, PhD, proud to serve as mentor
When she first enrolled as a freshman undergraduate student at West Virginia University, Carmella Evans-Molina, MD, PhD, never imagined she would become an award-winning diabetes researcher.
FDA approves expanded use of Cibinqo for adolescents with atopic dermatitis
The FDA has approved a supplemental new drug application to expand the use of abrocitinib for adolescents with atopic dermatitis when other systemic drug products are not adequate or advisable, according to a press release.
‘List doesn’t stop’ for JAK inhibitor potential in dermatology
MIAMI BEACH, Fla. — The past year has seen explosive development in Janus kinase inhibitors for dermatologic conditions, and it is possible they could continue to have indications throughout the specialty, according to a speaker here.
Abrocitinib demonstrates rapid efficacy in treating atopic dermatitis
A 200 mg dose of abrocitinib met stringent efficacy endpoints among substantial portions of patients with moderate to severe atopic dermatitis, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.